Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

APGE·NASDAQ

$88.21

+7.9%
HealthcareBiotechnology

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$5.46B
EPS-4.2200
P/E Ratio-20.90
Earnings Date08/10/2026

apge

Cash at Beginning of Period

Last Annual Value

142.08M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. Competitors Analysis of Cash at Beginning of Period

APGE · NASDAQ
CompanyCash at Beginning of Period
CAGR 3Y
CAGR 5Y
CAGR 10Y
142.08M
-2.2%N/AN/A 
286.82M
-28.5%-8.8%N/A
184.16M
10.2%-24.0%7.0%
192.67M
-0.4%49.4%N/A
CELC logo
Celcuity Inc.
NASDAQ:CELC
22.52M
-2.9%14.1%16.1%
257.07M
42.9%37.7%N/A
87.93M
81.9%12.3%32.0%
Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. Fair Value Envelope

APGE · NASDAQ

Our analysis suggests that APGE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $88.2061, this represents a potential HIDDEN relative to our calculated worth for Apogee Therapeutics, Inc..

Intrinsic Value
Current Price: $88.2061